The Asia Pacific IBS-C drug market is anticipated to grow considerably and record the highest CAGR of 9.96% during the projected period, 2020-2028. Due to the presence of highly populated countries like India and China, the region offers a great opportunity for healthcare sectors, and especially there is a great utilization of IBS drugs, owing to increasing lifestyle oriented diseases.

ASIA-PACIFIC IBS-C DRUG MARKET FORECAST 2020-2028

Asia Pacific Ibs-c Drug Market by Drug Type (Overview (Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives, Others (Psyllium)), Pipeline Drug Analysis: Plecanatide)  by Prescription Type (Prescribed Drugs, Over the Counter Drugs) by Geography

Request free sample

Report Summary

The Asia Pacific IBS-C drug market is anticipated to grow considerably and record the highest CAGR of 9.96% during the projected period, 2020-2028. Due to the presence of highly populated countries like India and China, the region offers a great opportunity for healthcare sectors, and especially there is a great utilization of IBS drugs, owing to increasing lifestyle oriented diseases.

In order to understand the potential of the IBS-C market of Asia Pacific further, the region is segmented into India, Vietnam, Japan, Indonesia, China, Thailand, South Korea, Australia & New Zealand, and the rest of Asia Pacific. In China, IBS is very common and found in high incidence in common people facing constipation, painful bowel movement, and chronic gastronomical disorder. The rising awareness about IBS treatment and patients seeking the treatment are driving the market share for the IBS treatment. In countries like Japan, with the increasing number of patients and the awareness of adverse effects of IBS, the well-aware population are opting for medical solutions in the form of medicines, laxatives, non- therapeutic alternatives, and the popular traditional Chinese medicines. In India, most patients with IBS are middle-aged men with constipation or diarrhea. In countries like South Korea, the prevalence of irritable bowel disease is increasing. Although extraintestinal manifestations (EIM) are more prevalent among IBD patients, EIMs has not yet been investigated in Korea.

Yuhan Corp., headquartered in Seoul, South Korea, researches, manufactures, develops, and markets pharmaceutical products. It offers APIs and finished products in the domestic and international market.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • MARKET DEFINITION
      • KEY DRIVERS
        • MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
        • IBS CAN BE A HERITABILITY ISSUE
        • AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
      • KEY RESTRAINTS
        • STRICT FDA REGULATIONS
        • UNAWARENESS AND IGNORANCE AMONG PEOPLE
    1. KEY ANALYTICS
      • KEY INVESTMENT INSIGHTS
      • PORTER’S FIVE FORCE ANALYSIS
        • BUYER POWER
        • SUPPLIER POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • REGULATORY FRAMEWORK
    2. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    3. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
      • OTHER DRUG TYPES
    4. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • THAILAND
        • VIETNAM
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA PACIFIC
    1. COMPANY PROFILES
      • CATALENT PHARMACEUTICALS SOLUTIONS
      • ABBOTT LABORATORIES
      • NOVARTIS PHARMA AG
      • ASTELLAS PHARMACEUTICALS
      • ARDELYX, INC.
      • SYNTHETIC BIOLOGICS, INC.
      • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
      • BAMA-GEVE, SLU
      • FERRING BV
      • IRONWOOD PHARMACEUTICALS, INC.
      • SALIX PHARMACEUTICALS LTD.
      • NORGINE B.V.
      • PROMETHEUS LABORATORIES, INC.
      • ALBIREO PHARMA, INC.
      • YUHAN CORP.
      • ASTRAZENECA PLC
      • THE MENARINI GROUP
      • ONO PHARMACEUTICAL CO. LTD.
      • ACTAVIS NORDIC A/S

     

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – IBS-C DRUG

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 4: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 5: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 6: ASIA PACIFIC IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

    TABLE 8: ASIA PACIFIC IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: ASIA PACIFIC IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)

    TABLE 11: PRODUCT PROFILE (LINACLOTIDE)

    TABLE 12: ASIA PACIFIC IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 13: ASIA PACIFIC IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 14: PRODUCT PROFILE (BISACODYL)

    TABLE 15: PRODUCT PROFILE (SENNA)

    TABLE 16: ASIA PACIFIC IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 17: ASIA PACIFIC IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 18: PRODUCT PROFILE (LACTULOSE)

    TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)

    TABLE 20: PRODUCT PROFILE (PSYLLIUM)

    TABLE 21: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 22: ASIA PACIFIC IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    LIST OF FIGURES

    FIGURE 1: DRUGS PULLED OFF FROM THE MARKET

    FIGURE 2: KEY INVESTMENT INSIGHTS

    FIGURE 3: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: ASIA PACIFIC IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019

    FIGURE 7: ASIA PACIFIC IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)

    FIGURE 8: ASIA PACIFIC IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)

    FIGURE 9: ASIA PACIFIC IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)

    FIGURE 10: ASIA PACIFIC IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)

    FIGURE 11: ASIA PACIFIC IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019

    FIGURE 12: ASIA PACIFIC IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)

    FIGURE 13: ASIA PACIFIC IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)

    FIGURE 14: ASIA PACIFIC IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020 -2028 (IN $ MILLION)

    FIGURE 15: ASIA PACIFIC IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 16: ASIA PACIFIC IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)

    FIGURE 17: ASIA PACIFIC IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020 -2028 (IN $ MILLION)

    FIGURE 18: ASIA PACIFIC IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)

    FIGURE 19: ASIA PACIFIC IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)

    FIGURE 20: ASIA PACIFIC IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)

    FIGURE 21: ASIA PACIFIC IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 22: CHINA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 23: CHINESE MEDICINE TCM TREATMENT FOR IBS

    FIGURE 24: JAPAN IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 25: INDIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 26: SOUTH KOREA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 27: INDONESIA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 28: THAILAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 29: VIETNAM IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 30: AUSTRALIA & NEW ZEALAND IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 31: REST OF ASIA PACIFIC IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • THAILAND
        • VIETNAM
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA PACIFIC
    1. MARKET BY PRESCRIPTION TYPE
      • PRESCRIBED
        • BRANDED
        • GENERIC
      • OVER THE COUNTER
    2. MARKET BY DRUG TYPE
      • LUBIPROSTONE
      • LINACLOTIDE
      • STIMULANT LAXATIVES
        • BISACODYL
        • SENNA
      • OSMOTIC LAXATIVES
        • LACTULOSE
        • POLYETHYLENE GLYCOL
      • OTHER DRUG TYPES

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS